Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
04 05 2022
04 05 2022
Historique:
received:
08
12
2021
accepted:
07
04
2022
entrez:
4
5
2022
pubmed:
5
5
2022
medline:
7
5
2022
Statut:
epublish
Résumé
As SARS-CoV-2 continues to spread and vaccines are rolled-out, the "double burden" of disparities in exposure and vaccination intersect to determine patterns of infection, immunity, and mortality. Serology provides a unique opportunity to measure prior infection and vaccination simultaneously. Leveraging algorithmically-selected residual sera from two hospital networks in the city of San Francisco, cross-sectional samples from 1,014 individuals from February 4-17, 2021 were each tested on two assays (Ortho Clinical Diagnostics VITROS Anti-SARS-CoV-2 and Roche Elecsys Anti-SARS-CoV-2), capturing the first year of the epidemic and early roll-out of vaccination. We estimated, using Bayesian estimation of infection and vaccination, that infection risk of Hispanic/Latinx residents was five times greater than of White residents aged 18-64 (95% Credible Interval (CrI): 3.2-10.3), and that White residents over 65 were twice as likely to be vaccinated as Black/African American residents (95% CrI: 1.1-4.6). We found that socioeconomically-deprived zipcodes had higher infection probabilities and lower vaccination coverage than wealthier zipcodes. While vaccination has created a 'light at the end of the tunnel' for this pandemic, ongoing challenges in achieving and maintaining equity must also be considered.
Identifiants
pubmed: 35508478
doi: 10.1038/s41467-022-30051-x
pii: 10.1038/s41467-022-30051-x
pmc: PMC9068757
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2451Subventions
Organisme : NIAID NIH HHS
ID : K23 AI076614
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG046372
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI144048
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2022. The Author(s).
Références
medRxiv. 2021 Mar 05;:
pubmed: 33688675
Vaccine. 2017 Feb 22;35(8):1167-1174
pubmed: 28126202
Clin Infect Dis. 2021 Nov 16;73(10):1784-1789
pubmed: 33560346
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):431-436
pubmed: 33764963
Clin Infect Dis. 2021 Jul 30;73(Suppl 2):S127-S135
pubmed: 32821935
JAMA. 2021 Oct 12;326(14):1400-1409
pubmed: 34473201
Soc Sci Med. 2021 Mar;272:113638
pubmed: 33414032
PLoS One. 2021 Sep 20;16(9):e0257111
pubmed: 34543291
Ann Intern Med. 2020 Aug 4;173(3):233-234
pubmed: 32343767
Clin Infect Dis. 2021 Mar 1;72(5):e88-e95
pubmed: 33221832
Clin Infect Dis. 2021 Jul 15;73(2):324-327
pubmed: 32744615
Int J Equity Health. 2020 Jul 29;19(1):126
pubmed: 32727486
Nat Commun. 2021 Jun 11;12(1):3566
pubmed: 34117227
Soc Sci Med. 2017 Nov;193:70-79
pubmed: 29028558
Public Health. 2020 Jun;183:110-111
pubmed: 32502699
JAMA Netw Open. 2021 Oct 1;4(10):e2128575
pubmed: 34643719
Transl Behav Med. 2020 Aug 7;10(3):516-519
pubmed: 32542349
JAMA Netw Open. 2021 Oct 1;4(10):e2130343
pubmed: 34668949